Increased angiogenesis is important in the pathophysiology of solid tumors as well as hematological malignancies including acute myeloid leukemia (AML). Vascular Endothelial Growth Factor (VEGF) is the central mediator of angiogenesis that was suggested to play an important role in the pathogenesis of AML. In this study VEGF expression was analysed in 30 AML patients and 10 healthy controls. It was found to be significantly elevated in AML patients compared to the control group, and was significantly higher in patients with high total leukocytic count and blast cell count. Although we couldn't detect a predictive value of VEGF as regards the clinical outcome in terms of achieving complete remission, disease-free survival, or event free survival, our results suggested a role of VEGF in the pathophysiology of AML.